Endo (ENDP) Slides as CEO 'Transition Plan' Includes CEO Retiring...and Nothing Else
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Join SI Premium – FREE
Endo Pharmaceuticals Holdings (NASDAQ: ENDP) shares are lower in late trading following announcement of a "CEO Transition Plan."
Here's the plan:
1. CEO David P. Holveck is retiring;
2. That's all.
Endo said it wouldn't conduct a search, evaluating both internal and external candidates. The entire thing has the feeling of what Intel (Nasdaq: INTC) pulled a few weeks back, except that Holveck, age 67, shouldn't have been a surprise to investors.
Shares are down 2.5 percent late Wednesday.
Here's the plan:
1. CEO David P. Holveck is retiring;
2. That's all.
Endo said it wouldn't conduct a search, evaluating both internal and external candidates. The entire thing has the feeling of what Intel (Nasdaq: INTC) pulled a few weeks back, except that Holveck, age 67, shouldn't have been a surprise to investors.
Shares are down 2.5 percent late Wednesday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Synaptics CFO resigns amid pending ON Semiconductor merger
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Insiders' Blog, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
